We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EC Expands Label for Pfizer’s Xalkori Lysogene Gains Orphan Drug, Rare Pediatric Disease Designations FDA Holds Public Meeting on Patient-Focused Drug Development for Psoriasis Cellceutix Gains FDA Fast Track for Oral Mucositis Candidate Exelixis Awarded EC Approval for Cotellic for Metastatic Melanoma